SVB Securities analyst Jonathan Chang maintained a Hold rating on Adaptimmune Therapeutics (ADAP – Research Report) today and set a price target of $3.00. The company’s shares closed last Monday at $1.54.
According to TipRanks.com, Chang is ranked 0 out of 5 stars with an average return of -21.4% and a 17.7% success rate. Chang covers the Healthcare sector, focusing on stocks such as Karyopharm Therapeutics, Mersana Therapeutics, and Bicycle Therapeutics.
Adaptimmune Therapeutics has an analyst consensus of Hold, with a price target consensus of $5.25, which is a 200.0% upside from current levels. In a report released today, Mizuho Securities also maintained a Hold rating on the stock with a $9.00 price target.
The company has a one-year high of $6.86 and a one-year low of $1.65. Currently, Adaptimmune Therapeutics has an average volume of 1.02M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.
Read More on ADAP:
- Mersana Therapeutics (MRSN) Gets a Buy Rating from SVB Securities
- Analysts Offer Insights on Services Companies: Thoughtworks Holding (TWKS) and Chuy’s Holdings (CHUY)
- Shopify Stock: A Look at the Valuation
- Fortis (FTS) was Upgraded to a Buy Rating at Veritas Investment Research
- Galiano Gold (GAU) Receives a Hold from Berenberg Bank